Transcriptome at the time of hepatitis C virus recurrence may predict the severity of fibrosis progression after liver transplantation

Valeria Mas, Daniel Maluf, Kellie J. Archer, Amiee Potter, Jihee Suh, Ricardo Gehrau, Valeria Descalzi, Federico Villamil

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Allograft gene expression analysis may provide insights into the mechanisms involved in liver damage during hepatitis C virus recurrence (HCVrec) after orthotopic liver transplantation (OLT) and allow the identification of patients who have a higher risk of developing severe disease. Forty-three OLT recipients with hepatitis C virus (HCV) were evaluated. Genomewide gene expression analysis was performed with formalin-fixed, paraffin-embedded (FFPE) liver biopsy samples obtained from 21 OLT recipients with HCV at the time of clinical HCVrec, which was defined as increased alanine aminotransferase levels and detectable HCV RNA levels in serum. Patients were classified into 3 groups according to the severity of the fibrosis in the liver biopsies at 36 months post-OLT: group 1 (G1) for mild fibrosis (F0-F1), group 2 for moderate fibrosis (F2), and group 3 (G3) for severe fibrosis (F3-F4). No significant differences were observed between the groups with respect to donor age, histology during HCVrec, treated episodes of acute cellular rejection, or immunosuppression therapy. The results were validated in the remaining 22 OLT recipients with HCV using quantitative real-time polymerase chain reaction. Fifty-seven beadtypes showed significantly different expression (P < 0.001) between the groups during HCVrec. In G3, the gene expression of interleukin-28RA (IL-28RA), IL-28, and angiotensin- converting enzyme was up-regulated. Samples from G1 and G3 were used to determine whether a multigenetic classifier could be derived to predict the group class. The final model included the intercept and 9 bead types. Pairwise scatter plots of these 9 bead types revealed that G1 and G3 were well separated with respect to each gene. Our analysis has demonstrated the utility of a set of molecular markers indicating HCVrec severity early after OLT.

Original languageEnglish (US)
Pages (from-to)824-835
Number of pages12
JournalLiver Transplantation
Volume17
Issue number7
DOIs
StatePublished - Jul 1 2011

Fingerprint

Transcriptome
Hepacivirus
Liver Transplantation
Fibrosis
Recurrence
Gene Expression
Biopsy
Interleukins
Liver
Peptidyl-Dipeptidase A
Alanine Transaminase
Liver Cirrhosis
Paraffin
Immunosuppression
Formaldehyde
Allografts
Real-Time Polymerase Chain Reaction
Histology
Tissue Donors
RNA

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hepatology
  • Transplantation

Cite this

Transcriptome at the time of hepatitis C virus recurrence may predict the severity of fibrosis progression after liver transplantation. / Mas, Valeria; Maluf, Daniel; Archer, Kellie J.; Potter, Amiee; Suh, Jihee; Gehrau, Ricardo; Descalzi, Valeria; Villamil, Federico.

In: Liver Transplantation, Vol. 17, No. 7, 01.07.2011, p. 824-835.

Research output: Contribution to journalArticle

Mas, Valeria ; Maluf, Daniel ; Archer, Kellie J. ; Potter, Amiee ; Suh, Jihee ; Gehrau, Ricardo ; Descalzi, Valeria ; Villamil, Federico. / Transcriptome at the time of hepatitis C virus recurrence may predict the severity of fibrosis progression after liver transplantation. In: Liver Transplantation. 2011 ; Vol. 17, No. 7. pp. 824-835.
@article{7418561d8fc640a5b0637a22649e7e7c,
title = "Transcriptome at the time of hepatitis C virus recurrence may predict the severity of fibrosis progression after liver transplantation",
abstract = "Allograft gene expression analysis may provide insights into the mechanisms involved in liver damage during hepatitis C virus recurrence (HCVrec) after orthotopic liver transplantation (OLT) and allow the identification of patients who have a higher risk of developing severe disease. Forty-three OLT recipients with hepatitis C virus (HCV) were evaluated. Genomewide gene expression analysis was performed with formalin-fixed, paraffin-embedded (FFPE) liver biopsy samples obtained from 21 OLT recipients with HCV at the time of clinical HCVrec, which was defined as increased alanine aminotransferase levels and detectable HCV RNA levels in serum. Patients were classified into 3 groups according to the severity of the fibrosis in the liver biopsies at 36 months post-OLT: group 1 (G1) for mild fibrosis (F0-F1), group 2 for moderate fibrosis (F2), and group 3 (G3) for severe fibrosis (F3-F4). No significant differences were observed between the groups with respect to donor age, histology during HCVrec, treated episodes of acute cellular rejection, or immunosuppression therapy. The results were validated in the remaining 22 OLT recipients with HCV using quantitative real-time polymerase chain reaction. Fifty-seven beadtypes showed significantly different expression (P < 0.001) between the groups during HCVrec. In G3, the gene expression of interleukin-28RA (IL-28RA), IL-28, and angiotensin- converting enzyme was up-regulated. Samples from G1 and G3 were used to determine whether a multigenetic classifier could be derived to predict the group class. The final model included the intercept and 9 bead types. Pairwise scatter plots of these 9 bead types revealed that G1 and G3 were well separated with respect to each gene. Our analysis has demonstrated the utility of a set of molecular markers indicating HCVrec severity early after OLT.",
author = "Valeria Mas and Daniel Maluf and Archer, {Kellie J.} and Amiee Potter and Jihee Suh and Ricardo Gehrau and Valeria Descalzi and Federico Villamil",
year = "2011",
month = "7",
day = "1",
doi = "10.1002/lt.22309",
language = "English (US)",
volume = "17",
pages = "824--835",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Transcriptome at the time of hepatitis C virus recurrence may predict the severity of fibrosis progression after liver transplantation

AU - Mas, Valeria

AU - Maluf, Daniel

AU - Archer, Kellie J.

AU - Potter, Amiee

AU - Suh, Jihee

AU - Gehrau, Ricardo

AU - Descalzi, Valeria

AU - Villamil, Federico

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Allograft gene expression analysis may provide insights into the mechanisms involved in liver damage during hepatitis C virus recurrence (HCVrec) after orthotopic liver transplantation (OLT) and allow the identification of patients who have a higher risk of developing severe disease. Forty-three OLT recipients with hepatitis C virus (HCV) were evaluated. Genomewide gene expression analysis was performed with formalin-fixed, paraffin-embedded (FFPE) liver biopsy samples obtained from 21 OLT recipients with HCV at the time of clinical HCVrec, which was defined as increased alanine aminotransferase levels and detectable HCV RNA levels in serum. Patients were classified into 3 groups according to the severity of the fibrosis in the liver biopsies at 36 months post-OLT: group 1 (G1) for mild fibrosis (F0-F1), group 2 for moderate fibrosis (F2), and group 3 (G3) for severe fibrosis (F3-F4). No significant differences were observed between the groups with respect to donor age, histology during HCVrec, treated episodes of acute cellular rejection, or immunosuppression therapy. The results were validated in the remaining 22 OLT recipients with HCV using quantitative real-time polymerase chain reaction. Fifty-seven beadtypes showed significantly different expression (P < 0.001) between the groups during HCVrec. In G3, the gene expression of interleukin-28RA (IL-28RA), IL-28, and angiotensin- converting enzyme was up-regulated. Samples from G1 and G3 were used to determine whether a multigenetic classifier could be derived to predict the group class. The final model included the intercept and 9 bead types. Pairwise scatter plots of these 9 bead types revealed that G1 and G3 were well separated with respect to each gene. Our analysis has demonstrated the utility of a set of molecular markers indicating HCVrec severity early after OLT.

AB - Allograft gene expression analysis may provide insights into the mechanisms involved in liver damage during hepatitis C virus recurrence (HCVrec) after orthotopic liver transplantation (OLT) and allow the identification of patients who have a higher risk of developing severe disease. Forty-three OLT recipients with hepatitis C virus (HCV) were evaluated. Genomewide gene expression analysis was performed with formalin-fixed, paraffin-embedded (FFPE) liver biopsy samples obtained from 21 OLT recipients with HCV at the time of clinical HCVrec, which was defined as increased alanine aminotransferase levels and detectable HCV RNA levels in serum. Patients were classified into 3 groups according to the severity of the fibrosis in the liver biopsies at 36 months post-OLT: group 1 (G1) for mild fibrosis (F0-F1), group 2 for moderate fibrosis (F2), and group 3 (G3) for severe fibrosis (F3-F4). No significant differences were observed between the groups with respect to donor age, histology during HCVrec, treated episodes of acute cellular rejection, or immunosuppression therapy. The results were validated in the remaining 22 OLT recipients with HCV using quantitative real-time polymerase chain reaction. Fifty-seven beadtypes showed significantly different expression (P < 0.001) between the groups during HCVrec. In G3, the gene expression of interleukin-28RA (IL-28RA), IL-28, and angiotensin- converting enzyme was up-regulated. Samples from G1 and G3 were used to determine whether a multigenetic classifier could be derived to predict the group class. The final model included the intercept and 9 bead types. Pairwise scatter plots of these 9 bead types revealed that G1 and G3 were well separated with respect to each gene. Our analysis has demonstrated the utility of a set of molecular markers indicating HCVrec severity early after OLT.

UR - http://www.scopus.com/inward/record.url?scp=79959825133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959825133&partnerID=8YFLogxK

U2 - 10.1002/lt.22309

DO - 10.1002/lt.22309

M3 - Article

VL - 17

SP - 824

EP - 835

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 7

ER -